ImmuPharma (LON:IMM) Trading 34.1% Higher - Here's Why

Key Points

• ImmuPharma's stock price surged by 34.1% on Tuesday, climbing to a last traded price of GBX 10.81 ($0.15) with a significant increase in trading volume.
• The company reported a net margin of 3,519.56% but had a negative return on equity of 131.41%, while analysts project a substantial loss per share for the current year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting Lupus and other related conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded up 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 57,593,953 shares were traded during trading, an increase of 656% from the average session volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Up 28.8%

The stock has a market cap of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The business has a 50 day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.